行情

SYRS

SYRS

Syros Pharms
NASDAQ

实时行情|Nasdaq Last Sale

6.10
+0.36
+6.27%
盘后: 6.14 +0.04 +0.66% 16:50 04/03 EDT
开盘
5.73
昨收
5.74
最高
6.46
最低
5.73
成交量
29.55万
成交额
--
52周最高
11.93
52周最低
4.260
市值
2.65亿
市盈率(TTM)
-3.2438
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测SYRS价格均价为12.17,最高价位17.00,最低价为8.00。

EPS

SYRS 新闻

更多
  • 欧佩克+会议推迟 沙特与俄罗斯紧张局势升级 周一油价料将暴跌
  • 新浪美股 · 2小时前
  • 美媒称联邦政府动用《国防生产法》与州政府抢购医疗物资
  • 央视 · 3小时前
  • 迪拜将人员流动限制措施扩大至24小时限制
  • 新浪美股 · 3小时前
  • 特朗普称将申请更多中小企业纾困资金
  • 央视 · 5小时前

所属板块

制药
-0.14%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

SYRS 简况

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company's drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, solid tumors, inflammatory diseases and other diseases to find optimal points of therapeutic intervention in patients.
展开

微牛提供Syros Pharmaceuticals Inc(NASDAQ-SYRS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的SYRS股票新闻,以帮助您做出投资决策。